Vaccinating in disease-free regions: A vaccine model with application to yellow fever

Journal of the Royal Society Interface

Volumn 4, Issue 17, 2007, Pages 1119-1125

  Codeço, Claudia T ^a   Luz, Paula M ^b   Coelho, Flavio ^a   Galvani, Alison P ^b   Struchiner, Claudio ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b YALE UNIVERSITY   (United States)

Author keywords

Brazil; Decision analysis; Emerging infectious diseases; Yellow fever

Indexed keywords

YELLOW FEVER VACCINE;

ARTICLE; BRAZIL; DISEASE PREDISPOSITION; EPIDEMIC; HEALTH PROGRAM; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION RATE; INFECTION RISK; MEDICAL DECISION MAKING; PROBABILITY; RISK ASSESSMENT; URBANIZATION; VACCINATION; VECTOR CONTROL; YELLOW FEVER;

EID: 37349110000     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2007.0234     Document Type: Article

References (16)

1. Camacho, L. A. B., da Silva Freire, M., da Luz Fernandes Leal, M., de Aguiar, S. G., do Nascimento, J. P., Iguchi, T., de Azevedo Lozana, J., Farias, R. H. G. & for the Study of Yellow Fever Vaccines, C. G. 2004 Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev. Saude Publica 38, 671-678.
2. Camacho, L. A. B., de Aguiar, S. G., da Silva Freire, M., da Luz Fernandes Leal, M., do Nascimento, J. P., Iguchi, T., Lozana, J. A., Farias, R. H. G. & for the Study of Yellow Fever Vaccines, C. G. 2005 Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev. Saude Publica 39, 413-420.
3. Caswell, H. 2000 Matrix population models: construction, analysis and interpretation. Sunderland, MA: Sinauer Associates.
4. Codeço, C. T., Luz, P. M. & Struchiner, C. J. 2004 Risk assessment of yellow fever urbanization in Rio de Janeiro, Brazil. Trans. R. Soc. Trop. Med. Hyg. 98, 702-710. (doi:10.1016/j.trstmh.2003.12.019)
5. de Oliveira, R. L., Vazeille, M., de Filippis, A. M. B. & Failloux, A. B. 2002 Oral susceptibility to yellow fever virus of Aedes aegypti from Brazil. Mem. Inst. Oswaldo Cruz. 97, 437-439.
6. Engel, A. R., Vasconcelos, P. F. C., McArthur, M. A. & Barrett, A. D. T. 2006 Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 24, 2803-2809. (doi:10.1016/j.vaccine. 2006.01.009)
7. Galler, R. et al. 2001 Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290, 309-319. (doi:10.1006/viro.2001.1168)
8. Luz, P. M., Codeço, C. T., Massad, E. & Struchiner, C. J. 2003 Uncertainties regarding dengue modeling in Rio de Janeiro, Brazil. Mem. Inst. Oswaldo Cruz. 98, 871-878. (doi:10.1590/S0074- 02762003000700002)
9. Marchevsky, R. S., Freire, M. S., Coutinho, E. S. F. & Galler, R. 2003 Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 316, 55-63. (doi:10.1016/S0042-6822(03)00583-X)
10. Massad, E., Coutinho, F. A., Burattini, M. N. & Lopez, L. F. 2001 The risk of yellow fever in a dengue-infested area. Trans. R. Soc. Trop. Med. Hyg. 95, 370-374. (doi:10.1016/S0035-9203(01)90184-1)
11. Massad, E., Coutinho, F. A. B., Burattini, M. N., Lopez, L. F. & Struchiner, C. J. 2005 Yellow fever vaccination: how much is enough? Vaccine 23, 3908-3914. (doi:10.1016/j.vaccine.2005.03.002)
12. Poole, D. & Raftery, A. E. 2000 Inference for deterministic simulation models: the bayesian melding approach. J. Am. Stat. Assoc. 95, 1244-1255. (doi:10.2307/2669764)
13. Salmon, D. A. & Omer, S. B. 2006 Individual freedoms versus collective responsibility: immunization decision-making in the face of occasionally competing values. Emerg. Themes Epidemiol. 3, 13. (doi:10.1186/1742-7622-3-13)
14. Salmon, D. A., Teret, S. P., MacIntyre, C. R., Salisbury, D., Burgess, M. A. & Halsey, N. A. 2006 Compulsory vaccination and conscientious or philosophical exemptions: past, present, future. Lancet 367, 436-442. (doi:10.1016/S0140-6736(06)68144-0)
15. Struchiner, C. J., Luz, P. M., Dourado, I., Sato, H. K., Aguiar, S. G., Ribeiro, J. G. L., Soares, R. C. R. & Codeço, C. T. 2004 Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol. Infect. 132, 939-946. (doi:10.1017/S0950268804002602)
16. Vasconcelos, P. F. C. 2003 Yellow fever. Rev. Soc. Bras. Med. Trop. 36, 275-293. (doi:10.1590/S0037-86822003000200012)